Galectin Therapeutics Inc. GALT

GALT Company Overview

Galectin Therapeutics Inc. is a U.S.-based clinical-stage biotechnology company focused on developing therapies that target galectin proteins, particularly galectin-3, which are implicated in fibrosis, inflammation, and cancer progression. The company operates within the biotechnology and biopharmaceutical industries, with its primary focus on liver disease and oncology-related applications. Its lead product candidate, belapectin, is being developed primarily for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. The company’s research platform centers on carbohydrate-based compounds designed to inhibit galectin-mediated disease pathways.

The company traces its origins to research into galectin biology and carbohydrate chemistry and later adopted the name Galectin Therapeutics Inc. after previously operating under other corporate structures tied to biotechnology development activities. Over time, the company narrowed its strategic emphasis toward liver disease, particularly advanced fibrosis and cirrhosis associated with MASH. Galectin Therapeutics positions itself as a specialized developer of galectin inhibitors, with strategic differentiation based on its intellectual property portfolio and clinical focus on fibrotic diseases where approved therapeutic options remain limited.